证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220501 | --- | --- | --- | |----------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | 媒体采访 | 业绩说明会 | | 类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 5 月 18 日 | | | 地点 | 宝莱特公司会议室、腾讯会议 | | | 参与单位名称 | 光大医药 - 吴佳青、通用投资 | - 李悦、大亚湾创新投 - 罗嘉辉、孙锦华、顾 | | | 嘉琪、李青、大亚湾创新投 伟琛、鲁文雯、田万彪、世域投资 俊、中泰证券 - | ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220602 | --- | --- | --- | |-----------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系 | 媒体采访 | 业绩说明会 | | 活动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 6 月 16 日 | | | 地点 | 光大证券丨宝莱特 - | 2022 年中期投资策略会网络路演 | | 参与单位名 | | 光大证券研究所：吴佳青、张瀚予、曹聪聪；上海喜世润投资：张亚北；人 | | 称 | | 保资产：吴锋；中意资产：刘佳；广发基金：孙琳；瀚伦投资：任靖；华商 基金：马步 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220601 | --- | --- | --- | |----------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | 媒体采访 | 业绩说明会 | | 类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 6 月 1 日 | | | 地点 | 宝莱特公司会议室 | | | 参与单位名称 | | 安信基金：池陈森；云棲资本：刘超；国信证券：陈曦炳、张超；鹏华 基金：李建国；申万宏源：戴宁莎；中信证券：周霞、陈心澜。 | | 上市公司接待人 | | 董事兼财务总监兼副总裁燕传平先生、董事会秘书兼副总裁杨永兴先 | ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220702 | --- | --- | --- | |--------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 7 月 21 日、 | 2022 年 7 月 22 日、 2022 年 7 月 25 日。 | | 地点 | 宝莱特公司会议室、腾讯会议。 | | | 参与单位名称 | | 华商基金：孙蔚、李海伟；长盛基金：周思聪、李雨辰等；信达澳亚基金： 李东升等；阳光资产：张剑姝、赵孟甲、杨伦 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220701 | --- | --- | --- | |-----------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220901 | --- | --- | --- | |--------------|------------------------------|--------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 9 月 15 日 | | | 地点 | 腾讯会议 | | | 参与单位名称 | | 瀚信资产管理集团有限公司：邓澄江；深圳九旭资产管理有限公司：李嘉； | | | | 广东信展私募基金管理有限公司：邱隆平；广州传山私募基金管理有限公 | | | | 司：黄石章；广东新价值投资有限公司：张旭；宁波磐石投资管理有限公 | | | | 司：李进鹏；上海龙龟投资管理有限公司：李宗平；东莞市顺风资产管理 | | | | 有 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20220902 | --- | --- | --- | |--------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2022 年 9 月 23 日 | | | | | | | 地点 | 宝莱特公司会议室 | | | 参与单位名称 | | 广东上市公司协会：封志敏、赵思皓；深圳龙宏投资管理有 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20221101 | --- | --- | --- | |--------------|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采 ...

Financial Performance - Revenue for Q3 2022 reached ¥310,129,849.78, an increase of 12.00% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 81.37% to ¥3,102,960.94 for Q3 2022, and by 85.29% to ¥10,209,825.88 for the year-to-date[5] - Basic earnings per share for Q3 2022 was ¥0.0176, down 84.56% year-on-year[5] - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, down 94.32% to ¥912,452.08 for Q3 2022[5] - The company’s net profit attributable to shareholders decreased by 85.29% year-on-year to CNY 10,209,825.88[10] - Earnings per share fell by 87.49% to CNY 0.0594 compared to the same period last year[10] - Net profit for the period was ¥11,313,848.94, a decrease of 83.8% from ¥69,702,953.84 in the same period last year[29] - The company reported a total comprehensive income of CNY 9,958,812.38 for the quarter, down from CNY 70,453,736.98 in the previous year[30] Assets and Equity - Total assets increased by 29.11% to ¥2,220,057,386.60 compared to the end of the previous year[5] - Owner's equity attributable to shareholders rose by 56.49% to ¥1,398,829,875.57 compared to the end of the previous year[5] - Total assets at the end of the reporting period amounted to CNY 2.22 billion, an increase of 29.11% compared to the beginning of the year[19] - The equity attributable to shareholders of the parent company increased to ¥1,398,829,875.57, compared to ¥893,887,780.38, reflecting a growth of 56.7%[27] Cash Flow - Cash flow from operating activities for the year-to-date was ¥70,858,113.61, an increase of 13.19%[5] - The company’s cash and cash equivalents increased by 96.35% to ¥660,823,547.60 due to the impact of capital increase during the reporting period[9] - Cash flow from operating activities for the period was CNY 70,858,113.61, up from CNY 62,602,875.04 year-over-year[31] - Cash inflow from operating activities totaled CNY 957,719,586.87, compared to CNY 847,532,618.27 in the previous year[31] - Cash outflow from operating activities was CNY 886,861,473.26, an increase from CNY 784,929,743.23 in the same period last year[31] - Cash flow from financing activities generated a net inflow of CNY 390,649,337.70, significantly higher than CNY 5,088,425.36 in the previous year[32] - The ending balance of cash and cash equivalents was CNY 558,616,935.14, compared to CNY 374,286,764.42 at the end of the same period last year[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,788[13] - The largest shareholder, Yan Jinyuan, holds 26.83% of the shares, amounting to 47,136,790 shares[13] - The top 10 unrestricted shareholders hold a total of 35,352,592 shares, with Yan Jinyuan holding the largest share of 11,784,198 shares[14] - The company reported that 1,106,394 shares were released from restrictions for shareholder Zeng Haiyan on August 18, 2022[16] - The total number of restricted shares at the end of the period is 35,352,592 for Yan Jinyuan, with a 25% annual unlock rate[16] - The company has a significant number of shares held by institutional investors, including 2,712,765 shares held by China Merchants Bank[17] - The company has implemented a stock incentive plan with a 25% annual unlock rate for certain executives, including Fu Jianwei and Liang Jin[16] - The company has a total of 3,340,425 shares held by Shenzhen Qianhai Jiuyin Investment Fund Management Co., Ltd., which are also subject to restrictions[17] - The company’s major shareholders include Wang Shi and Huang Zhimin, who hold 4,331,520 and 3,457,446 shares respectively[14] - The company has not disclosed any additional relationships among the top 10 shareholders beyond the known marital relationship between Yan Jinyuan and Wang Shi[14] - The company’s stock structure includes both common and restricted shares, with specific release dates for certain shareholders[16] - The company’s overall shareholder structure indicates a strong presence of both individual and institutional investors, reflecting confidence in its market position[14] Operational Highlights - In the first three quarters of 2022, the company achieved operating revenue of CNY 868.12 million, a year-on-year increase of 10.81%[19] - The health monitoring segment reported sales revenue of CNY 281.27 million, a year-on-year decrease of 7.95%, while the nephrology medical segment saw sales revenue of CNY 570.66 million, a year-on-year increase of 22.60%[19] - The company plans to enhance its marketing team and continue localizing overseas marketing talent to better promote its brand[20] - The company will focus on product technology advantages and increase R&D efforts to develop high-end products that address core pain points in healthcare[20] - The company raised a total of CNY 539.99 million through a private placement, with a net amount of CNY 528.05 million after deducting issuance costs[21] - The company has increased its investment in its wholly-owned subsidiary, Shenzhen Baoyuan Medical Equipment Co., Ltd., by CNY 25 million for marketing and logistics projects[22] Costs and Expenses - Total operating costs amounted to ¥861,473,525.00, up from ¥700,270,798.80, reflecting a significant increase of 23%[28] - Research and development expenses for the period were ¥60,725,652.63, an increase of 29.2% from ¥46,992,755.18[28] - Sales expenses increased by 57.48% to CNY 111,425,269.96 due to higher personnel and travel costs[10] - Financial expenses showed a significant decrease of 393.22%, resulting in a gain of CNY -7,218,504.35, attributed to increased bank deposit interest and foreign exchange gains[10] - Cash paid for fixed asset purchases increased by 53.34% to CNY 161,234,794.82, reflecting higher equipment procurement expenses[10] Liabilities - Short-term borrowings decreased by 58.17% to ¥54,122,561.04 as a result of repayment of bank loans[9] - Total liabilities rose to ¥744,213,215.71, up from ¥727,126,342.41, indicating a growth of 2%[27] - The company’s long-term borrowings increased to ¥48,000,000.00 from ¥32,000,000.00, representing a growth of 50%[27] Audit Information - The company did not conduct an audit for the Q3 report[33]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥557.99 million, representing a 10.16% increase compared to ¥506.52 million in the same period last year[22]. - The net profit attributable to shareholders decreased significantly by 86.53% to ¥7.11 million from ¥52.74 million year-on-year[22]. - The net profit after deducting non-recurring gains and losses fell by 92.54% to ¥3.79 million compared to ¥50.74 million in the previous year[22]. - The net cash flow from operating activities increased by 73.56% to ¥64.15 million, up from ¥36.96 million in the same period last year[22]. - The total assets of the company at the end of the reporting period reached approximately ¥2.30 billion, a 34.00% increase from ¥1.72 billion at the end of the previous year[22]. - The net assets attributable to shareholders increased by 61.50% to ¥1.44 billion from ¥893.89 million at the end of the previous year[22]. - Basic earnings per share decreased by 88.42% to ¥0.0418 from ¥0.3610 in the same period last year[22]. - The weighted average return on net assets dropped to 0.53% from 5.59% year-on-year[22]. - The company reported a total revenue of 11,863 million RMB for the first half of 2022[68]. Market and Industry Insights - The global medical device market size was approximately $493.5 billion in 2020, with a year-on-year growth of 8.96%[36]. - The global dialysis industry market size is projected to approach €100 billion by 2025, with a steady annual growth rate of approximately 4%[39]. - The medical device market in China reached approximately ¥772.1 billion in 2020, making it the second-largest market globally[37]. - The blood purification market in China is experiencing rapid growth, with the number of patients receiving hemodialysis treatment increasing from 447,400 in 2016 to 749,600 by the end of 2021, reflecting a compound annual growth rate of 12%[40]. Product Development and Innovation - The company emphasizes new product and technology development, adhering to ISO9001 and ISO13485 standards for research and development control[33]. - The company is committed to developing high-end, differentiated, and intelligent products, with ongoing R&D for new devices such as the G series monitors and peritoneal dialysis machines[54]. - The company launched several new products, including the P series monitors and D800 series dialysis devices, which received 6 medical device registration certificates from regulatory authorities[52][53]. - The company is actively integrating high-quality resources in the blood purification industry through both organic growth and mergers and acquisitions[45]. - The company has established the Baolait Medical Technology Research Institute to enhance collaboration between industry, academia, and healthcare, optimizing its R&D capabilities[55]. Regulatory Compliance and Certifications - As of June 30, 2022, the company holds 41 authorized invention patents, 246 utility model patents, and 29 design patents, ensuring strong core competitiveness[54]. - The company has obtained a total of 66 medical device registration certificates, ensuring strong core competitiveness[71]. - The company is the first listed enterprise in the domestic blood purification field to obtain a medical device registration certificate for a dialysis fluid filter, which has also received CE certification from the EU[72]. Strategic Initiatives and Future Outlook - The company aims to establish a comprehensive ecosystem in the blood dialysis field while consolidating its medical monitoring equipment business[31]. - Future plans include establishing a digital, networked, and intelligent demonstration factory in Zhuhai based on 5G and industrial internet technologies[59]. - The company plans to enhance its market presence through the introduction of innovative products and expansion into new markets[68]. - The company aims to increase its market share by 10% in the next fiscal year through strategic partnerships and collaborations within the healthcare sector[66]. Challenges and Risks - The company has highlighted potential risk factors and countermeasures in its report, urging investors to pay attention to investment risks[3]. - Rising raw material costs pose a significant risk to the company's profitability, despite efforts to control these costs through supply chain integration[118]. - The implementation of centralized procurement policies for high-value medical consumables may lead to price and profit margin declines, impacting the company's performance if it fails to win bids[115]. Corporate Governance and Shareholder Engagement - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[4]. - The company granted 2.52 million restricted stock units to 130 incentive targets, later adjusted to 2.48 million units for 129 targets[130]. - The company held its annual general meeting on May 18, 2022, with an investor participation rate of 30.43%[124]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[125].